本帖最后由 老马 于 2013-3-13 13:43 编辑
1 S" C# o6 B! ~" B9 ~4 g$ y- Q6 W- F! i) ^: t
健择(吉西他滨)+顺铂+阿瓦斯汀& I8 W. ?/ _! A0 o# r( t
Gemzar +Cisplatin + Avastin
) d2 r/ B% p5 |( C4 z: W6 d9 Ghttp://annonc.oxfordjournals.org/content/21/9/1804.full( T* j$ ?: X* C! e f! q6 p7 f
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
) w1 g( Z" U) L$ _9 A; {# dPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
) |$ f) E8 _' T. s% lResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 6 y1 G- s# @) z+ u6 k. O y! A
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 842)
, h; H8 s7 v' q8 L2 ~
华为网盘附件:
$ e% g i4 L7 F9 n【华为网盘】ava.JPG
+ d. w+ {( f7 ?4 a |